For patients with FGF19‐ positive HCC, fisogatinib treatment was well tolerated and was a good cancer intervention.[37] Our study confirmed that FGF19 blockade with fisogatinib efficiently suppresses the liver metastasis induced by FGF19‐overexpressing CRC cells in a mouse model. Here, FGF19 is linked to hepatocellular carcinoma.